Treatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells  Biological: WJ‐MSCs  Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment  5, all, 18 years and older  Treatment  Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.
WJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously  I  Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results
Secondary (8 weeks): RT‐PCR results  NCT04313322/Recruiting, Mar16‐Sep30 2020